- Home
- TILE vs EWTX Comparison
TILE vs EWTX Comparison
Compare TILE & EWTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TILE
- EWTX
- Stock Information
- Founded
- TILE 1973
- EWTX 2017
- Country
- TILE United States
- EWTX United States
- Employees
- TILE N/A
- EWTX N/A
- Industry
- TILE Home Furnishings
- EWTX Biotechnology: Pharmaceutical Preparations
- Sector
- TILE Consumer Discretionary
- EWTX Health Care
- Exchange
- TILE Nasdaq
- EWTX Nasdaq
- Market Cap
- TILE 1.6B
- EWTX 1.6B
- IPO Year
- TILE N/A
- EWTX 2021
- Fundamental
- Price
- TILE $26.90
- EWTX $23.65
- Analyst Decision
- TILE Buy
- EWTX Buy
- Analyst Count
- TILE 1
- EWTX 10
- Target Price
- TILE $32.00
- EWTX $37.30
- AVG Volume (30 Days)
- TILE 457.6K
- EWTX 1.3M
- Earning Date
- TILE 10-31-2025
- EWTX 11-06-2025
- Dividend Yield
- TILE 0.30%
- EWTX N/A
- EPS Growth
- TILE 33.41
- EWTX N/A
- EPS
- TILE 1.92
- EWTX N/A
- Revenue
- TILE $1,372,471,000.00
- EWTX N/A
- Revenue This Year
- TILE $7.40
- EWTX N/A
- Revenue Next Year
- TILE $4.74
- EWTX N/A
- P/E Ratio
- TILE $13.96
- EWTX N/A
- Revenue Growth
- TILE 5.11
- EWTX N/A
- 52 Week Low
- TILE $17.24
- EWTX $10.60
- 52 Week High
- TILE $30.20
- EWTX $35.50
- Technical
- Relative Strength Index (RSI)
- TILE 54.40
- EWTX 75.81
- Support Level
- TILE $25.39
- EWTX $21.72
- Resistance Level
- TILE $27.03
- EWTX $23.36
- Average True Range (ATR)
- TILE 0.77
- EWTX 1.49
- MACD
- TILE 0.12
- EWTX 0.32
- Stochastic Oscillator
- TILE 91.34
- EWTX 95.62
About TILE Interface Inc.
Interface Inc is engaged in the design, production, and sale of carpet tiles. It also provides Luxury Vinyl tiles and rubber flooring. The company mainly targets corporate and noncorporate office markets, including government, education, healthcare, hospitality, and retailers. Its geographical segments include the Americas, Europe, and Asia-Pacific. It has two operating and reportable segments- namely Americas (AMS) and Europe, Africa, Asia and Australia (collectively EAAA). Key revenue is generated from AMS segment.
About EWTX Edgewise Therapeutics Inc.
Edgewise Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on the discovery, development, and commercialization of treatments for severe, rare muscle disorders. It is developing orally bioavailable, small molecule therapies for musculoskeletal diseases. The company's product candidates are Sevasemten and EDG-7500. Sevasemten is an orally administered small molecule designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker). The company is currently studying Sevasemten in Phase 2 trials, which are being held in the U.S. and Israel and in certain countries in Europe and Australasia.